This educational activity is directed toward neurointensivists, critical care clinicians, and neurologists. Cardiologists, nurse practitioners, physician assistant, nurses, primary care physicians, and other health care professionals involved in the treatment of patients experiencing bleeding episodes are invited to participate.
Increased risk of bleeding is a known complication of anticoagulation therapies, including direct oral anticoagulants (DOACs). Although DOACs demonstrated favorable safety and efficacy profiles in the absence of a specific reversal agent, situations such as overdose, serious bleeding, or the need for immediate surgery warranted a call to action to develop DOAC reversal agents. This call to action was answered, and there are now 2 FDA-approved DOAC reversal agents. Ongoing education about DOAC reversal is vital for clinicians involved in critical care. In this educational program, experts discuss the agents and best practices for the use of DOAC reversal in patients with intracranial hemorrhage.
This educational activity is an archive of the live virtual symposium held on October 27, 2021.
Upon completion of this activity, participants should be better able to: